IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
==== Gene gun delivery and biolistics ==== Gene gun delivery/Biolistics has been an attractive method for gene delivery due to its non-viral properties, and in addition to viral transduction, is one of the most common methods. This allows for less adverse immune responses and a smaller chance of viral infection compared to viral-based transfer methods. Rather than using a viral vector, this technique utilizes physical methods, specifically using helium propulsion to deliver transformation vectors. Gene gun delivery has been traditionally used for the generation of transgenic plants as it has been able to efficiently and effectively penetrate the cell walls. More recently, this technique has been successful in animal cells that cannot tolerate high-level bombardment, where instead DNA gold particles are delivered at lower helium pressure. This method has been successfully used both in vitro and in vivo.
In another New York Times article, Nate Cohn analyzed exit polls showing Trump's gains among non-white and young voters, suggesting Trump's populist message resonated with many voters previously considered part of the Democratic Party's base. Jen Psaki, who served as Biden's first press secretary, suggested that Harris focusing on Anti-Trump Republicans was not a winning strategy. Charlie Cook, founder of the nonpartisan The Cook Political Report, said that swing voters broke in favor of Trump due to anger over inflation associated with the Biden-Harris administration, causing Trump to sweep the swing states. However, Democrats did better in down-ballot races, meaning Trump did not have a strong coattail effect. The Atlantic's Ronald Brownstein argued that the Democratic Party's success in the 2022 midterm elections, when Trump was not on the ballot, had led them to underestimate Trump's support. Democrats also performed better than Harris in down-ballot races, suggesting voters likely assigned their blame over the economy on the Biden-Harris administration rather than the Democratic Party at-large. The BBC's Courtney Subramanian said Harris "couldn't shake the anti-Biden sentiment that permeated much of the electorate", that she "failed to deliver a convincing argument about why she should lead the country", did not state a strategy to combat economic frustrations, and failed to address widespread concerns over immigration.
The first of China's nuclear weapons tests took place in 1964, and its first hydrogen bomb test occurred in 1967 at Lop Nur. Tests continued until 1996, when the country signed the Comprehensive Nuclear-Test-Ban Treaty (CTBT), but did not ratify it. The number of nuclear warheads in China's arsenal remains a state secret. There are varying estimates of the size of China's arsenal. The Bulletin of the Atomic Scientists and Federation of American Scientists estimated in 2024 that China has a stockpile of approximately 438 nuclear warheads, while the United States Department of Defense put the estimate at more than 500 operational nuclear warheads, making it the third-largest in the world. China's policy has traditionally been one of no first use while maintaining a deterrent retaliatory force targeted for countervalue targets. According to a 2023 study by the National Defense University, China's nuclear doctrine has historically leaned toward maintaining a secure second-strike capability.
=== Biofilms formation and cyclic di-GMP === As in most Gram negative bacteria, P. aeruginosa biofilm formation is regulated by one single molecule: cyclic di-GMP. At low cyclic di-GMP concentration, P. aeruginosa has a free-swimming mode of life. But when cyclic di-GMP levels increase, P. aeruginosa start to establish sessile communities on surfaces. The intracellular concentration of cyclic di-GMP increases within seconds when P. aeruginosa touches a surface (e.g.: a rock, plastic, host tissues...). This activates the production of adhesive pili, that serve as "anchors" to stabilize the attachment of P. aeruginosa on the surface. At later stages, bacteria will start attaching irreversibly by producing a strongly adhesive matrix. At the same time, cyclic di-GMP represses the synthesis of the flagellar machinery, preventing P. aeruginosa from swimming. When suppressed, the biofilms are less adherent and easier to treat. The biofilm matrix of P. aeruginosa is composed of nucleic acids, amino acids, carbohydrates, and various ions. It mechanically and chemically protects P. aeruginosa from aggression by the immune system and some toxic compounds. P. aeruginosa biofilm's matrix is composed of up to three types of sugar polymers (or "exopolysaccharides") named PSL, PEL, and alginate. Which exopolysaccharides are produced varies by strain.
Sources: en.wikipedia.org
forces had invaded in October during the coup. Activist Barbara Trent disputed this finding, saying in a 1992 Academy Award-winning documentary The Panama Deception that the Panamanian surveys were completed in wealthy, English-speaking neighborhoods in Panama City, among Panamanians most likely to support U.S. actions. Human Rights Watch described the reaction of the civilian population to the invasion as "generally sympathetic".
== Detection and treatment == Several detection methods can be used in order to determine the concentration of saxitoxin within an organism (be it shellfish or human), both in vivo and in vitro. The most commonly used in vivo method is the mouse bioassay, which provides quantitative and qualitative data in case of a (suspected) PSP neurotoxin exposure; in vitro receptor binding assays provide equivalent data, while being animal-friendly. PSP neurotoxins can also be detected by high-performance liquid chromatography (HPLC), amongst other forms of chromatography. Shellfish containing 80 or more micrograms of saxitoxin per 100g of edible shellfish tissue are deemed to be unsafe for human consumption. Currently, there is no antidote for PSP neurotoxins. Most PSP patients suffer only minor symptoms, these lasting until the toxin is eliminated from the body. With minor exposure, spontaneous recovery can thus be expected. In the relatively rare case of clinically significant respiratory paralysis, symptomatic treatment in the form of oxygen supplementation and/or mechanical ventilation should be employed until symptoms subside.
Myasthenia gravis (MG) is a long-term neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, and difficulties in talking and walking. Onset can be sudden. A small percentage of patients can have an enlarged thymus or rarely a thymoma. Myasthenia gravis is an autoimmune disease of the neuromuscular junction which results from antibodies that block or destroy nicotinic acetylcholine receptors (AChR) at the junction between the nerve and muscle. This prevents nerve impulses from triggering muscle contractions. Most cases are due to immunoglobulin G1 (IgG1) and IgG3 antibodies that attack AChR in the postsynaptic membrane, causing complement-mediated damage and muscle weakness. Rarely, an inherited genetic defect in the neuromuscular junction results in a similar condition known as congenital myasthenia. Babies of mothers with myasthenia may have symptoms during their first few months of life, known as neonatal myasthenia or more specifically transient neonatal myasthenia gravis. Diagnosis can be supported by blood tests for specific antibodies, the edrophonium test, electromyography (EMG), or a nerve conduction study. Mild forms of myasthenia gravis may be treated with medications known as acetylcholinesterase inhibitors, such as neostigmine and pyridostigmine. But these drugs only provide symptomatic relief.
==== 400–499 ==== Greater London, Kent and Surrey (County Boundaries) Order 1993 (S.I. 1993/400) Billing Authorities (Alteration of Requisite Calculations and Transitional Reduction Scheme) (England) Regulations 1993 (S.I. 1993/401) Staffordshire, Warwickshire and West Midlands (County Boundaries) Order 1993 (S.I. 1993/402) Education (Designated Institutions) Order 1993 (S.I. 1993/404) Organic Products (Amendment) Regulations 1993 (S.I. 1993/405) Outer Space Act 1986 (Fees) (Amendment) Regulations 1993 (S.I. 1993/406) Local Authorities (Recovery of Costs for Public Path Orders) Regulations 1993 (S.I. 1993/407) Social Security (Introduction of Disability Living Allowance) (Amendment) Regulations 1993 (S.I. 1993/408) National Health Service Trusts (Membership and Procedure) (Scotland) Amendment Regulations 1993 (S.I. 1993/412) National Health Service Trusts (Originating Capital Debt) Order 1993 (S.I. 1993/413) Lloyd's Underwriters (Tax) (1990–91) Regulations 1993 (S.I. 1993/415) Seeds (National Lists of Varieties) (Fees) (Amendment) Regulations 1993 (S.I. 1993/416) National Health Service (Optical Charges and Payments) Amendment Regulations 1993 (S.I. 1993/418) National Health Service (Dental Charges) Amendment Regulations 1993 (S.I. 1993/419) National Health Service (Charges for Drugs and Appliances) Amendment Regulations 1993 (S.I. 1993/420) Finance Act 1985 (Interest on Tax) (Prescribed Rate) Order 1993 (S.I. 1993/421) Workmen's Compensation (Supplementation) (Amendment) Scheme 1993 (S.I. 1993/422) Glasgow Caledonian University (Establishment) (Scotland) Order 1993 (S.I.
=== Treatment === Consumption of Amanita virosa is a medical emergency requiring hospitalization. There are four main categories of therapy for poisoning: preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage. However, due to the delay between ingestion and the first symptoms of poisoning, it is commonplace for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. There is some evidence that intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. Silibinin prevents the uptake of amatoxins by hepatocytes, thereby protecting undamaged hepatic tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis. N-acetylcysteine has shown promise in combination with other therapies.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.